2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Issue 8 (8th July 2021)

• Record Type: Journal Article
• Authors: Chung, Sharon A.; Langford, Carol A.; Maz, Mehrdad; Abril, Andy; Gorelik, Mark; Guyatt, Gordon; Archer, Amy M.; Conn, Doyt L.; Full, Kathy A.; Grayson, Peter C.; Ibarra, Maria F.; Imundo, Lisa F.; Kim, Susan; Merkel, Peter A.; Rhee, Rennie L.; Seo, Philip; Stone, John H.; Sule, Sangeeta; Sundel, Robert P.; Vitobaldi, Omar I.; Warner, Ann; Byram, Kevin; Dua, Anisha B.; Husainat, Nedaa; James, Karen E.; Kalot, Mohamad A.; Lin, Yih Chang; Springer, Jason M.; Turgunbaev, Marat; Villa‐Forte, Alexandra; Turner, Amy S.; Mustafa, Reem A.;
• Is Part Of: Arthritis care & research. Volume 73:Issue 8(2021)
• Page Start: 1088
• Page End: 1105
• Publication Date: 2021-07-08
• Subjects: Arthritis -- Periodicals; Rheumatism -- Periodicals; 616.72
• DOI: 10.1002/acr.24634
• Languages: English
• ISSNs: 2151-464X

Abstract

Abstract : Objective: To provide evidence‐based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody–associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Methods: Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results: We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low‐quality evidence supporting the recommendations. Conclusion: This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.